Fate Therapeutics clinical trials
The registry lists 25 studies whose lead sponsor is Fate Therapeutics. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 14, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 25studies on the registry
- 5open to participants now
- 1reach primary completion within a year
Get an email when these change. Save the Fate Therapeutics studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
What it is testing
The drugs Fate Therapeutics’s studies test, most open studies first — 11 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- 2 open · 3
- 0 open · 2
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
Show 1 moreShow fewer
- 0 open · 1
Coming up
1 of Fate Therapeutics’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- 1SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 25 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 419
- 20
- 21
- 22
- 23
- 24
- 25
- 226
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Fate Therapeutics.
- Fate Therapeutics25 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 25 of 25.
- A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisRecruitingNCT07570862Phase 2
- FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsRecruitingNCT07216105Phase 1
- FT839 in Autoimmune DiseasesRecruitingNCT07800871Phase 1/2
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseRecruitingNCT06308978Phase 1
- FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid TumorsRecruitingNCT06241456Phase 1
- FT819 in Subjects With B-cell MalignanciesActive, not recruitingNCT04629729Phase 1
- FT576 in Subjects With Multiple MyelomaCompletedNCT05182073Phase 1
- FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)CompletedNCT05950334Phase 1
- FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesTerminatedNCT04245722Phase 1
- FT516 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04023071Phase 1
- Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyTerminatedNCT04106167
- FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedNCT05069935Phase 1
- FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedNCT05395052Phase 1
- FT538 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04614636Phase 1
- FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedNCT04551885Phase 1
- FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaWithdrawnNCT05934097Phase 1
- FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 1
- Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesCompletedNCT02743351Phase 1/2
- Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular ImmunotherapyTerminatedNCT04093622
- The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.TerminatedNCT01627314Phase 2
- FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsCompletedNCT03319459Phase 1
- A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic DisordersTerminatedNCT02354443Phase 1
- A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic MalignanciesTerminatedNCT02354417Phase 1
- Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood UnitCompletedNCT01527838Phase 1
- Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.CompletedNCT00890500Phase 1